IL179602A0 - Cerberus/coco derivatives and uses thereof - Google Patents

Cerberus/coco derivatives and uses thereof

Info

Publication number
IL179602A0
IL179602A0 IL179602A IL17960206A IL179602A0 IL 179602 A0 IL179602 A0 IL 179602A0 IL 179602 A IL179602 A IL 179602A IL 17960206 A IL17960206 A IL 17960206A IL 179602 A0 IL179602 A0 IL 179602A0
Authority
IL
Israel
Prior art keywords
cerberus
coco
derivatives
coco derivatives
Prior art date
Application number
IL179602A
Other languages
English (en)
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of IL179602A0 publication Critical patent/IL179602A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
IL179602A 2004-05-27 2006-11-27 Cerberus/coco derivatives and uses thereof IL179602A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57506204P 2004-05-27 2004-05-27
PCT/US2005/018928 WO2005115439A2 (en) 2004-05-27 2005-05-27 Cerberus/coco derivatives and uses thereof

Publications (1)

Publication Number Publication Date
IL179602A0 true IL179602A0 (en) 2007-05-15

Family

ID=35451405

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179602A IL179602A0 (en) 2004-05-27 2006-11-27 Cerberus/coco derivatives and uses thereof

Country Status (8)

Country Link
US (4) US7316998B2 (OSRAM)
EP (1) EP1755648A2 (OSRAM)
JP (1) JP2008500373A (OSRAM)
KR (1) KR20070026650A (OSRAM)
AU (1) AU2005247508A1 (OSRAM)
CA (1) CA2567810A1 (OSRAM)
IL (1) IL179602A0 (OSRAM)
WO (1) WO2005115439A2 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833971B2 (en) 2006-12-08 2010-11-16 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
US9045553B2 (en) * 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
KR20200054317A (ko) * 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
WO2008106478A1 (en) * 2007-02-27 2008-09-04 Lanx, Llc Compositions and methods for modification of target cells and to their uses thereof
WO2008151119A2 (en) * 2007-06-01 2008-12-11 Lanx, Llc Compositions and methods for use of scar tissue in repair of weight bearing surfaces
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009105606A1 (en) * 2008-02-21 2009-08-27 Lanx, Llc Compositions and methods for use of scar tissue in repair of weight bearing surfaces
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US9149319B2 (en) * 2008-09-23 2015-10-06 Lanx, Llc Methods and compositions for stabilization of a vertebra
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
BRPI1011236A2 (pt) 2009-06-15 2019-07-09 4S3 Bioscience Inc métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1)
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
DE102010052941A1 (de) * 2010-11-18 2012-05-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Therapeutisches Protein
BR112014018427B1 (pt) 2012-01-27 2021-11-03 Biomarin Technologies B.V. Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3741375A1 (en) * 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
SMT202500263T1 (it) 2015-09-15 2025-09-12 Scholar Rock Inc Anticorpi anti-pro-miostatina/miostatina latente e loro usi
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
WO2017177013A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
KR102271635B1 (ko) * 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
DK3565592T5 (da) * 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
CN109758616B (zh) * 2019-03-05 2021-11-19 中国医学科学院北京协和医院 一种新型促进骨再生材料及其制备方法
TW202430247A (zh) 2022-12-22 2024-08-01 美商供石公司 肌肉生長抑制素活化之選擇性及強效抑制劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
WO1998034951A1 (en) 1997-02-11 1998-08-13 Amrad Operations Pty. Ltd. A new cytokine family and uses thereof
US6610510B1 (en) * 1997-04-29 2003-08-26 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
US5935852A (en) 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3511100A (en) * 1999-03-12 2000-10-04 Regeneron Pharmaceuticals, Inc. Novel nucleic acids and polypeptides
WO2002032929A2 (en) * 2000-10-19 2002-04-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the cer1 gene
EP1357828A2 (en) 2001-01-12 2003-11-05 University of Medicine and Dentistry of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
GB0111004D0 (en) 2001-05-04 2001-06-27 Univ Sheffield Screening method
US6513196B2 (en) * 2001-06-22 2003-02-04 Maytag Corporation Top cover hinge and method for using same
CN1161875C (zh) 2001-07-01 2004-08-11 周符明 开关稳功率电源
GB0118223D0 (en) 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
MXPA04003697A (es) 2001-10-31 2005-04-08 Alcon Inc Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
AU2003216345A1 (en) * 2002-02-21 2003-09-09 Wyeth Follistatin domain containing proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
NZ537597A (en) 2002-06-14 2008-07-31 Diversa Corp Xylanases, nucleic acids encoding them and methods for making and using them
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
EA009056B1 (ru) * 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
WO2004074460A2 (en) * 2003-02-19 2004-09-02 The Rockefeller University Nucleotide and protein sequences of coc genes and methods based thereon

Also Published As

Publication number Publication date
US20060025340A1 (en) 2006-02-02
US20090192080A1 (en) 2009-07-30
WO2005115439A9 (en) 2006-02-02
JP2008500373A (ja) 2008-01-10
WO2005115439A3 (en) 2007-09-13
EP1755648A2 (en) 2007-02-28
US20100183695A1 (en) 2010-07-22
US7981857B2 (en) 2011-07-19
AU2005247508A1 (en) 2005-12-08
WO2005115439A2 (en) 2005-12-08
KR20070026650A (ko) 2007-03-08
US20130029908A1 (en) 2013-01-31
US7316998B2 (en) 2008-01-08
CA2567810A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
IL179602A0 (en) Cerberus/coco derivatives and uses thereof
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
IL183216A0 (en) Nepetalactams and n-substituted derivatives thereof
IL185280A0 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
IL176872A (en) History of affluent and their use as insecticides
IL179640A0 (en) Metastin derivatives and use thereof
ZA200701820B (en) Substituted phenylaminothiazoles and use thereof
EP1951680A4 (en) NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
IL187776A0 (en) Benzamide derivatives and uses related thereto
IL188926A0 (en) Bicyclic bisamide derivatives and use thereof as insecticides
IL185492A0 (en) Cyclopentapyridine and tetrahydroquinoline derivatives
EP1951215A4 (en) HYDRAZONE DERIVATIVES AND ITS USES
IL183217A0 (en) Dihydronepetalactams and n-substituted derivatives thereof
PL1771421T3 (pl) Pochodne N-hydroksyamidowe i ich zastosowanie
ZA200606678B (en) 2-Pyridinylethylcarboxamide derivatives and their use as fungicides
EP1737565A4 (en) COS CLAUS CONFIGURATIONS AND METHODS
EP1951682A4 (en) NEW 2-AMINOPYRIMIDONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE
IL178765A0 (en) 2-pyridinylcycloalkylbenzamide derivatives and their use as fungicides
IL179497A0 (en) Carboranylporphyrins and uses thereof
IL177709A0 (en) Caspase inhibitors and uses thereof
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0316910D0 (en) Fluorocombretastatin and derivatives thereof
EP1810976A4 (en) BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
IL177105A0 (en) Coumarin derivative and use thereof
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses